Rarebase Names Chris Moxham as Chief Executive Officer
The Californer/10256423

PALO ALTO, Calif., Oct. 4, 2023 ~ Chris Moxham, Ph.D., President and Chief Scientific Officer of Rarebase, a platform drug development biotechnology company that is revolutionizing discovering and developing medicines at unprecedented speed, scale, and capital efficiency, has been appointed Chief Executive Officer effective immediately. Onno Faber, co-founder of Rarebase, has been appointed to the newly created role of Chief Technology Officer.

Moxham expressed his privilege in leading Rarebase in its next phase of growth. He stated that the company is on the path to dramatically accelerate the way the world does drug discovery and has already uncovered potential treatments for hundreds of rare diseases. The next phase will see its 'drug-gene atlas' enable AI-driven drug discovery at scale and will grow its world-class team further as it works tirelessly to serve the needs of everyone living with a rare disease.

Rarebase is focused on improving the lives of 400 million people living with a rare disease, 95% of whom don't have an effective treatment. With a product engine designed to discover treatments for hundreds of monogenic diseases simultaneously, Rarebase is squarely focused on the largest untapped drug discovery opportunity in human health: rare diseases.

More on The Californer

• California: Governor Newsom proclaims Mental Health Awareness Month
• Multi-Platinum Artist Harold Payne Releases Mother's Day Song "Angels Don't Always Wear Wings"
• Coinbase recommends using Winner Mining Classic hashrate for the benefit of everyone
• Charming Mountain Retreat Hits the Market – A Cozy Escape for All Seasons
• Nieves Ministries Leads with Faith to Fortify Safety, Education, and Puerto Rican Culture in Colorado

John Lee, Partner at JAZZ Venture Partners commented on Moxham's appointment as CEO saying that he is an exceptional leader who is highly regarded for his strategic vision and operational excellence. He added that now is the time for Rarebase to accelerate its growth and leverage the potential treatments it has already uncovered for hundreds of rare diseases. Lee also expressed his pleasure in having Onno assume the new role of Chief Technology Officer and thanked him for his unwavering passion for serving those living with a rare disease.

Moxham joined Rarebase in November 2021 as Chief Scientific Officer and was elevated to President in July 2023. His career spans more than 25 years in drug discovery, particularly cutting-edge science and drug hunting in large pharma and biotech companies such as Eli Lilly & Co., where he helped bring more than 10 molecules into clinical trials across multiple therapeutic areas and across both small and large molecules. He then served as Chief Scientific Officer at Fulcrum Therapeutics where he was responsible for full range of drug discovery activities including building preclinical portfolio through Phase 1 clinical trials; he was also scientific lead for FTX-6058 which is currently undergoing Phase 1 clinical testing for Sickle Cell Disease. Moxham was instrumental in creating multiple business development partnerships with investment community to achieve multiple rounds of financing for Fulcrum Therapeutics.

---

Show All News | Report Violation